MMP9 and endothelial dysfunction: This supports the hypothesis that, in patients at risk for cardiovascular disease such as hypertension, peripheral endothelial dysfunction extends to the bone marrow and may result in reduced NO bioavailability and, consequently, impaired MMP9-dependent (E)PC mobilization [11], [19].